Cibus (CBUS) Non-Current Assets (2016 - 2026)
Cibus (CBUS) posted Non-Current Assets of $293.0 million for Q4 2025, down 3.62% sequentially from $304.0 million in Q3 2025, and down 12.05% YoY from $333.1 million in Q4 2024.
Cibus (CBUS) Non-Current Assets (2016 - 2026) Analysis & Trends
Cibus has reported Non-Current Assets for 10 years, with the latest figure at $293.0 million in Q4 2025.
- Quarterly Non-Current Assets fell 12.05% year-over-year to $293.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.2 billion (down 28.51% YoY) and the FY2025 annual result came in at $293.0 million, down 12.05% from the prior year.
- Non-Current Assets fell to $293.0 million in Q4 2025 per CBUS's latest filing, from $304.0 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $761.8 million in Q3 2023 and troughed at $17.7 million in Q1 2023.
- A 5-year average of $256.1 million and a median of $298.5 million in 2025 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2023 and 2024: Non-Current Assets jumped 3961.0% in 2023, then tumbled 55.85% in 2024.
- Over 5 years, Non-Current Assets stood at $22.0 million in 2021, then decreased by 16.92% to $18.3 million in 2022, then surged by 2684.14% to $509.2 million in 2023, then plunged by 34.58% to $333.1 million in 2024, then declined by 12.05% to $293.0 million in 2025.
- According to Business Quant data, Non-Current Assets over the past three periods registered $293.0 million, $304.0 million, and $306.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 938.60 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 468.65 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 18.06 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 6.80 Bn |
| 10 | Cibus | 131.25 Mn | 110.82 Mn | - | 289.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 289.99 Mn |
| Dec 31, 2025 | 292.98 Mn |
| Sep 30, 2025 | 303.98 Mn |
| Jun 30, 2025 | 306.36 Mn |
| Mar 31, 2025 | 309.16 Mn |
| Dec 31, 2024 | 333.12 Mn |
| Sep 30, 2024 | 336.30 Mn |
| Jun 30, 2024 | 520.28 Mn |
| Mar 31, 2024 | 506.32 Mn |
| Dec 31, 2023 | 509.19 Mn |
| Sep 30, 2023 | 761.76 Mn |
| Jun 30, 2023 | 759.42 Mn |
| Mar 31, 2023 | 17.70 Mn |
| Dec 31, 2022 | 18.29 Mn |
| Sep 30, 2022 | 18.76 Mn |
| Jun 30, 2022 | 19.15 Mn |
| Mar 31, 2022 | 19.37 Mn |
| Dec 31, 2021 | 22.01 Mn |
| Sep 30, 2021 | 22.27 Mn |
| Jun 30, 2021 | 22.80 Mn |